CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma

Abstract Introduction Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune checkpoint inhibitors (ICIs) marked some advances but only for a limited fraction of patients. Improving response prediction to ICIs is currently a clinical need in DPM. Deletion of CDKN2A gene, in chr9p2...

Full description

Bibliographic Details

Published in:	Journal of Experimental & Clinical Cancer Research
Main Authors:	Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli, Roberto Piro, Massimiliano Paci, Nicola Facciolongo, Filippo Lococo, Alessia Ciarrocchi
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Diffuse pleural mesothelioma Tumor immune microenvironment Genetic alteration CDKN2A Immunotherapy
Online Access:	https://doi.org/10.1186/s13046-025-03522-4